BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#196 of 347

Matthew Sykes

Goldman Sachs · Equity Research Analyst
ProvisionalRating since 2022No new ratings since May 2025

Analyst rating accuracy & track record

Matthew Sykes is an equity research analyst at Goldman Sachs. Bullish Whales has scored 33 of their stock calls across 12 companies. Their picks beat their sector 37% of the time over the next 12 months, and their price targets were reached 51% of the time within a year.

Win % vs sector
37%
PT Hit % (12mo)
51%
Avg sector-excess
−8.4%
Scored calls
33
Tickers
12
Tier
Provisional

Track record

Bullish Whales has scored 33 of Matthew Sykes's stock calls across 12 companies, dating back to 2022. Their rated stocks beat their own sector 37% of the time over the next 12 months. On a typical call, a Sykes pick returned −8.4% more than its sector over the following year.

Of the scored calls, 25 were bullish (Buy) and 8 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
CTKBCytek Biosciences Inc
Sell$3.00May 2025−23.0%Hit
MYGNMyriad Genetics Inc
Buy$8.00May 2025−8.3%Hit
TWSTTwist Bioscience Corp
Buy$48.00May 2025+72.3%Hit
SHCSotera Health Co
Buy$17.00May 2025+9.2%Hit
NEONeoGenomics Inc
Buy$10.00Apr 2025+18.8%Hit
CDNACareDx Inc
Buy$26.00Apr 2025+12.2%Miss
NEONeoGenomics Inc
Buy$15.00Apr 2025−27.1%Miss
MYGNMyriad Genetics Inc
Buy$14.00Apr 2025−45.6%Miss
NEONeoGenomics Inc
Buy$18.00Jan 2025−22.8%Miss
MYGNMyriad Genetics Inc
Buy$18.00Jan 2025−62.2%Miss
NAUTNautilus Biotechnology Inc
Sell$1.75Dec 2024+13.3%Hit
MRVIMaravai Lifesciences Holdings Inc
Sell$4.25Dec 2024+34.9%Hit
VCYTVeracyte Inc
Buy$38.00Nov 2024+15.3%Hit
CDNACareDx Inc
Buy$35.00Oct 2024−33.8%Miss
CDNACareDx Inc
Buy$26.00Aug 2024−35.0%Hit
CDNACareDx Inc
Buy$16.00Jul 2024−26.6%Hit
DNAGinkgo Bioworks Holdings
Sell$0.30Jul 2024+9.0%Hit
QTRXQuanterix Corp
Buy$24.00Jul 2024−49.7%Miss
CTKBCytek Biosciences Inc
Buy$10.00Feb 2024−54.3%Miss
DNAGinkgo Bioworks Holdings
Sell$1.10Jan 2024+78.1%Hit
DNAGinkgo Bioworks Holdings
Sell$1.10Jan 2024+80.6%Hit
QGENQiagen NV
BuyDec 2023−7.1%
QTRXQuanterix Corp
Buy$34.00Sep 2023−73.8%Miss
QTRXQuanterix Corp
Buy$34.00Sep 2023−73.5%Miss
QTRXQuanterix Corp
Buy$30.00Aug 2023−59.5%Miss
DNAGinkgo Bioworks Holdings
Sell$1.25Jun 2023+84.8%Hit
DNAGinkgo Bioworks Holdings
Sell$1.25Jun 2023+79.6%Hit
QTRXQuanterix Corp
Buy$27.00May 2023−35.5%Hit
QTRXQuanterix Corp
Buy$27.00May 2023−35.2%Hit
CTKBCytek Biosciences Inc
Buy$12.00May 2023−33.7%Miss
CTKBCytek Biosciences Inc
Buy$14.00Mar 2023−28.9%Miss
CTKBCytek Biosciences Inc
Buy$17.00Aug 2022−40.2%Miss
CTKBCytek Biosciences Inc
Buy$15.00Jul 2022−27.9%Hit
Go to

Matthew Sykes: analyst track record FAQ

Is Matthew Sykes a good stock analyst?

Yes, by track record. Matthew Sykes ranks number 196 of 347 of the analysts Bullish Whales scores, with a BW Score of 25 out of 100. Past results do not guarantee future ones.

What is Matthew Sykes's win rate?

Matthew Sykes's win rate is 37%. Across 33 scored calls, their rated stocks beat their sector 37% of the time over the next 12 months. On a typical call they returned −8.4% more than the sector.

What stocks and sectors does Matthew Sykes cover?

Matthew Sykes covers 12 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Matthew Sykes's price targets accurate?

Matthew Sykes's price targets are reached within 12 months 51% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Matthew Sykes's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Matthew Sykes rank among Wall Street analysts?

Matthew Sykes ranks number 196 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30